In recent days, AbCellera and Bruker resolved their global patent dispute, with Bruker agreeing to pay US$36 million upfront plus ongoing royalties on Beacon Optofluidic platform sales. At the same ...
Investors may be wondering whether Bruker is quietly turning into a value opportunity, or if the recent noise is just a distraction from deeper issues in the business. The stock has bounced 6.8% over ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback